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Abstract
Malignant gliomas spawn disseminated microsatel-
lites, which are largely refractory to currently employed
therapies, resulting in eventual tumor recurrence and
death. The use of tumor-tropic neural stem cells (NSCs)
as delivery vehicles for therapeutic gene products
represents an attractive strategy specifically focused at
treating these residual neoplastic foci. We wished to
elucidate the biological cues governing NSC tropism
for glioma. In this context, we describe that tumor-
tropic NSCs comprise largely of astrocytic progenitors
expressing chemokine receptor 4 (CXCR4). Blocking
of CXCR4 significantly inhibits NSC migration toward
the tumor. These findings define specific character-
istics associated with the cell populations within
transplanted NSCs that demonstrate glioma-tracking
behavior.
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Introduction
Despite advances in surgical techniques and adjuvant ther-
apies, the prognosis for patients with malignant glial tumors
remains dismal. The median survival following diagnosis of
glioblastoma multiforme, the most common and aggressive
subtype of malignant glioma, is under 1 year, with a 2-year
survival rate approaching zero [1]. The failure of currently
employed therapeutic approaches, which center on surgical
resection followed by radiotherapy and/or chemotherapy, is
rooted in the highly disseminated nature of these tumors.
High-grade gliomas are highly infiltrative neoplasms, with
solitary tumor cells or clusters of neoplastic cells migrating
throughout the brain, often to significant distance from the
main tumor. Despite aggressive therapy, it is almost impos-
sible to successfully eliminate all of these tumor foci, which
eventually serve as reservoirs for near-universal tumor
recurrence, thereby contributing to the inevitable lethality of
this disease. Standard adjuvant treatments including radia-
tion and chemotherapy have, despite having modest effects
on long-term survival, been unable to effect any meaningful
impact on patient prognosis. The development of a success-
ful therapeutic modality for malignant glioma will, therefore,
center on the ability to devise a means of eliminating all
viable intracranial neoplastic reservoirs left behind after surgical
resection of the primary tumor mass. At present, this remains
a daunting task given the highly disseminated nature of the
disease process, and our current inability to adequately visual-
ize and therapeutically target every remaining tumor cell.
One promising means of specifically directing treatment to
migrating tumor satellites that has recently come to light
involves the use of neural stem cells (NSCs). NSCs are multi-
potent progenitor cells that can be derived from either embry-
onic, fetal, neonatal, or adult tissues and are capable of
long-term, sustained, in vitro propagation and terminal differ-
entiation into neurons and glia. We and others have demon-
strated that NSCs exhibit potent tropism for disseminating
glioma cells in vivo. When inoculated into established intracra-
nial gliomas in rodents, NSCs migrate away from the primary
site of injection and intersperse themselves with, or track into
proximity of, tumor satellites that have spread away from the
primary tumor mass [2,3]. NSCs engineered to secrete tumor
toxic chemokines can, in this manner, deliver these therapeutic
proteins directly to these disseminated neoplastic foci with
significant bioactivity. In particular, NSC populations secreting
the immunostimulatory cytokines IL-12 and IL-4 as well as the
proapoptotic protein TRAIL have been used to target migrating
tumor pockets with resulting decreases in tumor burden and
prolongation in survival [3–5]. These findings indicate that the
use of NSCs represents a potentially viable tool for specific
targeting of microscopic tumor nests that are otherwise re-
fractory to currently employed therapies. However, despite
promising results in preclinical murine models, the exact mech-
anisms governing the glioma tropic behavior of NSCs are
poorly understood. Additionally, our earlier observations dem-
onstrated that although many intratumorally inoculated NSCs
demonstrated robust migratory activity and tumor-tracking
capabilities, a significant proportion of transplanted NSCs did
not exhibit this behavior and remained localized to the site of
initial intracranial injection [3]. This could be secondary to
differing phenotypic profiles within our in vivo– inoculated
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NSC populations, which comprise of progenitor cells at
various levels of differentiation, ranging from uncommitted
multipotent precursors to cells that have initiated pathways
leading to assumption of either a neuronal or glial fate [6]. In
this context, we hypothesized that the tumor-tropic capacity
we observed within our NSC inoculae was likely exhibited
by a specific subpopulation of progenitor cells at a particu-
lar stage of differentiation. We also wished to investigate
whether in vivo glioma-tracking NSCs expressed any phe-
notypic markers such as chemokine receptors that would
indicate responsiveness to known chemotactic cues related
to NSC migration within the developing brain.
With the aim of further characterizing the tumor-tropic
component of the primary NSC populations utilized in earlier
therapeutic models of intracranial glioma, we now describe
that tumor-tracking NSCs comprise largely of astrocytic
precursors expressing significant levels of chemokine recep-
tor 4 (CXCR4), a chemokine receptor that governs cellular
migration and homing in a variety of cell types including
neuronal and glial precursors in the developing brain [7,8]. It
has recently been reported that the production by glioma
cells of stromal cell–derived factor-1 (SDF-1), the only
known ligand for CXCR4, correlated with histological grade,
tumor cell survival, and invasiveness [9,10]. Based on the
established roles of SDF-1 and CXCR4 in governing neuro-
nal and glial precursor migration in the developing central
nervous system (CNS) and the ability of invasive glioma cells
to secrete SDF-1, we hypothesized that elaboration by
disseminating tumor cells of this chemokine may play an
important role in chemoattracting migratory NSC popula-
tions. We now demonstrate that the tropism of NSCs toward
glioma-conditioned media in vitro can be inhibited by block-
ing cell surface CXCR4 receptors on NSCs, further confirm-
ing the relevance of this pathway in NSC migration. These
findings delineate important characteristics of the specific
cells within generalized NSC populations that exhibit the
therapeutically relevant behavior of ‘‘seek-and-destroy’’
tumor-tropic migration. The use of these markers and further
work on the characterization of these migratory sub-
populations will allow for refining of NSC subsets that are
Figure 1. NSCs are tropic for disseminating glioma in vivo. -Galactosidase–expressing NSCs were inoculated into established intracranial GL26 tumors in C57Bl/6
mice. Histological brain sections were then processed with routine X-gal staining, resulting in the development of a blue to dark blue precipitate within NSC-LacZ.
Sections were then counterstained with neutral red. Tumor tissue could be identified by intense red staining of neoplastic nuclei and visible dense aggregates of
tumor cells. T designates tumor, and N represents normal tissue. (A) Low-power image illustrating the presence of nonmigratory NSC-LacZ within main tumor mass
(T), demarcated by arrows. (B) Panel illustrates NSC-LacZ that have moved out of the main tumor mass and are moving into the proximity of tumor cell islets that
are migrating along the grey matter/white matter boundary, likely along a white matter tract (inset box). Note that migratory NSC-LacZ are still aggregated in
neurosphere-like accumulations. (C) Panel represents a high-power magnification of the inset box in (B). Dark blue NSC-LacZ aggregates are clearly visible in
close proximity to a disseminating tumor satellite (T). (D) High-power image of an independent tumor satellite (demarcated by arrowheads) at significant distance
from primary tumor site. Blue NSC-LacZ are visible within the tumor, clearly indicating that NSC-LacZ are capable of extensive migratory activity in vivo and can
intercalate themselves into disseminated tumor islets.
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increasingly responsive to cues that govern tropism for
disseminated tumor satellites in vivo, and therefore allow
for optimization of the therapeutic potential of NSCs in
this setting.
Materials and Methods
Cells and Culture Process
The humanU87MGglioma, murineGL26 glioma, NIH 3T3,
and 293 human embryonic kidney cell lines were cultured in
DM/F12 and Dulbecco’s Modified Eagle media (DMEM)
(Invitrogen, Carlsbad, CA), respectively supplemented
with 10% fetal bovine serum (FBS; Gemini Bio-Products,
Calabassas, CA), L-glutamine, and 1% penicillin/streptomycin
(Invitrogen). Conditionedmedia fromU87MG,GL26, NIH 3T3,
or 293 cultures were obtained from confluent 75-cm2 culture
flasks seeded 96 hours earlier with an approximately similar
numbers of cells. Cryopreserved human fetal NSCs were
obtained from Cambrex (Walkersville, MD) and murine NSCs
were harvested from the frontoparietal regions of day
15 mouse fetuses as described earlier [3]. NSCs were cul-
tured in DM/F12 media (Invitrogen) supplemented with B-27
growth factor (Invitrogen), 1% penicillin/streptomycin (Invitro-
gen), 20 to 30 ng/ml human ormurine epidermal growth factor,
20 to 30 ng/ml human basic fibroblast growth factor
(Peprotech, Rocky Hill, NJ), and 2 mg/ml heparin (Sigma,
St. Louis, MO). Murine NSCs were engineered to express
b-galactosidase by means of in vitro infection, with the LacZ
gene bearing replication-defective adenovirus as described
previously [3].
Establishment of In Vivo Glioma Model and NSC Inoculation
Six- to 8-week–old C57Bl/6 mice obtained from Charles
River Laboratories (Wilmington, MA) were anesthesized with
intraperitoneal ketamine and xylazine and stereotactically
inoculated with 5  104 GL26 cells in 3 ml of 1.2% methyl-
cellulose/MEM in the right corpus striatum as reported
previously [11]. At day 7 postimplantation, animals received
intratumoral inoculations of 2  105 neural stem cells
expressing b-galactosidase (NSC-LacZ) in 5 ml of serum
and virus-free media, injected directly into established tumor
using the same burr hole and stereotactic coordinates.
Animal use was performed in strict accordance with Institu-
tional Animal Care and Use Committee guidelines in force at
Cedars-Sinai Medical Center.
Histological Visualization of Tumor-Bearing Brain Sections
and Immunohistochemical Analysis of Glioma Tropic NSC
Phenotypes
Brains harvested from NSC-LacZ inoculated tumor-
bearing animals were frozen on dry ice, sectioned using a
cryostat, mounted on slides, and air-dried. For histological
visualization of LacZ-expressing NSCs, sections were stained
with X-gal as per routine protocol and then counterstainedwith
neutral red. Adjacent tissue sections were fixed in acetone.
Staining was performed as per standard immunohistochem-
istry protocols using primary antibodies against b-galactosi-
dase, Sox-2, SSEA-1, A2B5, E-NCAM, b-III tubulin, glial
fibrillary acidic protein (GFAP), CNPase, PDGFRa (Chemi-
con, Temecula, CA), CXCR4 (Torrey Pines Biolaboratories,
Houston, TX), EAAT1, and EAAT2 (Santa Cruz Biotechnolo-
gy, Santa Cruz, CA). Secondary staining was performed using
antibodies conjugated with the fluorophores FITC or Cy3
(Chemicon). Following staining, slides were mounted in aque-
ous mounting media (ICN Biochemicals, St. Louis, MO) and
visualized under a fluorescence microscope.
In Vitro Chemotaxis Experiments
All chemotaxis experiments were performed using a
chemotaxis chamber system (Neuro Probe, Gaithersburg,
MD) consisting of pairs of culture wells separated by a 5-mm
porous polycarbonate membrane. Lower wells were filled
with either GL26- or U87MG-conditioned media harvested as
described above. Fresh DMEM supplemented with 10%
FBS and 1% penicillin/streptomycin was used as a control
(unconditioned media). Following placement of the interven-
ing porous membrane, approximately 1.5  105 disaggre-
gated human or murine NSCs were added to the top
chambers. The chamber system was incubated at 37jC for
4 hours, after which media from lower wells were collected
and quantitatively analyzed for cell content using flow cytom-
etry against a defined number of fluorescent beads (BD
Pharmingen, San Diego, CA). This allowed for quantifica-
tion of the percentage of cells added to each top chamber
that had migrated to the bottom chamber. For neutralization
assays, anti–SDF-1 (250 mg/l) (neutralizing both known a and
b isoforms of the chemokine) and anti-CXCR4 (40 mg/ml)
monoclonal antibodies (R&D Systems, Minneapolis, MN)
were incubated with tumor-conditioned media or NSCs, re-
spectively, for 30 minutes at room temperature prior to the
assay. Control samples were incubated with identical con-
centrations of an isotype-matched nonspecific antibody (BD
Pharmingen). All experiments were performed in triplicate.
Results
NSCs That Migrate to Sites of Disseminating Tumor
Comprise of Astrocytic Precursors
We wished to determine whether the tumor tropism
exhibited by inoculated primary NSCs for in vivo–dissemi-
nating glioma was localized to a particular subpopulation at a
specific stage of differentiation. We histochemically analyzed
brain tissues from glioma-bearing animals that had received
intratumoral inoculations of NSC-LacZ. Routine X-gal stain-
ing revealed a significant proportion of b-galactosidase+ cells
that had migrated away from the site of inoculation into
proximity of islets of tumor cells (readily identifiable following
a neutral red counterstain) that were disseminating into and
through normal brain parenchyma (Figure 1), similar to
findings reported by us previously [3]. At the same time, a
residual population of NSC-LacZ remained localized to the
site of initial inoculation and did not exhibit this migratory,
tumor-tropic activity. We then subjected mirror sections of
the abovementioned samples (i.e., analogous histological
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samples that were not more than 20 to 30 mm removed from
the original samples visualized with X-gal staining) to immu-
nofluorescent histochemistry with a panel of antibodies
specific for markers reflective of proteins expressed at
varying stages of NSC differentiation. These included the
transcription factor Sox-2 and the cell surface antigen SSEA-1,
known to be expressed in uncommitted neural precursors;
A2B5 and E-NCAM, indicative of NSCs that have initiated
differentiation pathways toward astrocytic andneuronal fates,
respectively; GFAP, expressed in cells of astroglial lineages;
EAAT1 and EAAT2, glutamate transporter–related proteins
found in functional, differentiated astroglial cells; PDGFRa,
expressed in oligodendroglial precursors; CNPase, found
in differentiated oligodendrocytes; and b-III tubulin, ex-
pressed in precursor as well as differentiated neuronal cells
[6,12–15]. We specifically focused on expression of these
markers in b-galactosidase+ NSCs that had dispersed from
the primary inoculation tract and were now migrating in
conjunction with, or in proximity to, disseminating tumor
satellites, as observed on earlier X-gal–stained mirror sec-
tions. Our findings (summarized in Table 1) indicated that
although populations of NSCs expressing Sox-2 and SSEA-1
existed in the vicinity of the initial injection tract, the majority
of b-galactosidase expressing NSCs that were seen mi-
grating along with glioma outgrowths and satellites were
negative for these markers (not shown). Additionally, these
tumor-tropic NSC populations were strongly positive for
A2B5 and GFAP (Figure 2), although negative for the
oligodendroglial-associated proteins PDGFRa and CNPase
(not shown) as well as the neuronal marker b-III tubulin (not
shown), clearly indicating differentiation toward astrocytic
lineages. At the same time, these cells were negative for
the glial-specific glutamate transporter– related proteins
EAAT1 and EAAT2, known to be expressed in differentiated
astrocytes [13]. Conversely, populations of b-galactosidase+
cells with differentiated morphologies that expressed EAAT1
and EAAT2 along with GFAP and A2B5 could be observed in
the vicinity of the initial injection tract within the main tumor
mass (not shown), confirming that complete astrocytic dif-
ferentiation of inoculated precursors was, in fact, taking
place. However, the absence of EAAT1/EAAT2 expression
in glioma-tracking b-galactosidase+ cell populations, in con-
junction with expression of A2B5 and clear absence of fully
differentiatedmorphology, indicates that tumor-tropic cell pop-
ulations likely comprised of progenitor cells that had initiated,
but not completed, pathways toward astrocytic differentiation.
Tumor-Tracking NSCs Strongly Express CXCR4
Based on the demonstrated ability of SDF-1 secretion
from invasive glioma cells in promoting tumor invasiveness
and survival [10,16], as well as the established role of this
chemokine and its receptor CXCR4 in governing neuronal
and glial precursor migration within the developing brain
[7,8], we wished to investigate whether tumor-tracking
NSC-LacZ populations expressed CXCR4. We demonstrat-
ed that, although weak CXCR4 expression was visible both
on glioma cells as well as within NSC-LacZ populations
remaining within the main tumor mass (not shown), NSC-
LacZ that were tracking tumor outgrowths and satellites
strongly expressed this protein (Figure 2), indicating a po-
tential role for this receptor in governing NSC responsive-
ness to glioma-elaborated chemotactic cues.
NSC Migration Toward Tumor-Conditioned Media In Vitro
Can Be Inhibited by Blocking NSC Surface CXCR4
Receptors
Based on our observation that tumor-tropic NSC popula-
tions in vivo strongly expressed CXCR4, we wished to
determine whether this receptor played a role in NSC che-
motaxis toward glioma. In a two-chamber–based experi-
mental system wherein tumor-conditioned media was
separated from human and murine NSCs by a porous
membrane, we observed that NSC migration toward glioma
supernatant was significantly higher than that observed
toward unconditioned media (Figure 3), indicating chemo-
taxis toward a soluble factor present in tumor-conditioned
media. In contrast, there was no significant migration of NSC
migration toward conditioned media from the NIH 3T3 cell
line or from the 293 human embryonic kidney cell line, further
confirming the tumor-specific nature of NSC migration. With
the aim of determining whether neutralization of SDF-1 in
tumor supernatant would inhibit NSC migration toward glio-
ma-conditioned media, we incubated an anti–SDF-1 anti-
body with human U87MG glioma tumor supernatant and
then utilized this in a chemotaxis assay with human fetal
Table 1. Expression of Protein Markers Associated with Differentiation of NSCs on In Vivo Intratumorally Inoculated NSC-LacZ.
Differentiation
Stage–Related Marker
Differentiation Stage Staining on Non-migratory
NSC-LacZ
Staining on Glioma-Tropic
NSC-LacZ
Sox-2 Multipotent NSCs Weak, scattered cells Negative
SSEA-1 Multipotent NSCs Weak, scattered cells Negative
A2B5 Glial-restricted precursor,
astrocyte-restricted precursor,
astrocyte
Positive Positive
E-NCAM Neuronal precursor, neuron Weak, scattered cells Negative
PDGFRa Oligodendroglial precursor,
oligodendrocyte
Negative Negative
GFAP Astroglial precursor, astrocyte Strongly positive Strongly positive
-III tubulin Neuron Weak, scattered cells Negative
CNPase Oligodendrocyte Weak, scattered cells Negative
EAAT1/EAAT2 Differentiated glia (primarily astrocytes) Positive Negative
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NSCs. We found that in comparison to the significant NSC
chemotaxis seen toward the U87MG supernatant incubated
with an isotype-matched nonspecific antibody, addition of
the anti–SDF-1 neutralization antibody markedly decreased
NSC migration (Figure 3A), although this difference did not
meet statistical significance (P = 0.09; t-test). The addition of
anti–SDF-1 neutralization antibody did not significantly de-
crease murine fetal NSC migration toward GL26 glioma-
conditioned media (data not shown). However, following
incubation with an anti-CXCR4–blocking antibody, a signif-
icant decrease in NSC migration toward glioma-conditioned
media was seen both in the case of murine (Figure 2) as well
as human (not shown) fetal NSCs (P = 0.022 and P = 0.003,
respectively; t-test). In contrast, NSCs incubated with an
isotype-matched nonspecific antibody did not exhibit de-
creased migration toward tumor-conditioned media when
compared to untreated NSCs (Figure 3B). These data indi-
cate that blocking of CXCR4 significantly inhibits NSC taxis
toward glioma supernatant, suggesting an important role for
this receptor in the tumor-tropic behavior exhibited by these
cells. Our inability, however, to observe a statistically verifi-
able difference following neutralization of SDF-1 in tumor
supernatants may indicate either suboptimal neutralization of
soluble chemokine or presence within the tumor-conditioned
media of secondary ligands capable of inducing chemotaxis
through the CXCR4 pathway.
Discussion
In the setting of malignant glioma, the use of tumor-tropic
NSCs represents a promising approach capable of delivering
tumoricidal therapeutic agents directly to disconnected neo-
plastic foci. The ability of NSCs to track to isolated sites of
disseminated tumor is fundamental to the success of this
approach, and defining the mechanisms governing this
behavior will prove critical to refining this therapeutic option
for potential clinical translation. Recently, it has been
reported that high-grade gliomas secrete significant levels
of SDF-1, and that the expression of this protein and the
CXCR4 receptor correlated with the histological grade and
invasive capacity of these tumors, as well as tumor cell
survival [9,10,16]. Additionally, the interaction of CXCR4
and SDF-1 is a known factor involved in the migration of
NSCs [7], including astrocytic precursors, in the external
granular layer of the developing cerebellum [8]. We now
demonstrate that glioma-tracking populations of NSCs within
intratumorally injected primary NSC inoculae comprise of
cells with phenotypic expression profiles characteristic of as-
trocytic precursors, as well as strong expression of CXCR4,
and that the tumor-tropic capacity of these cells can be
inhibited by neutralization of surface CXCR4. These findings
clearly point to astrocytic progenitors as the candidate cells
exhibiting tumor-tracking capacity within transplanted
NSCs, which is in keeping with earlier findings that immature
astrocytes have the potential to migrate toward pathology
in the brain [17]. In this context, it is important to note, how-
ever, that Rao [12] has described the absence of GFAP
along with expression of A2B5 as characteristic of astrocyte-
restricted precursors within populations of NSCs. Our
results, in contrast, demonstrate expression of both A2B5
and GFAP within tumor-tropic NSCs along with an absence
of differentiated morphology and negligible expression of
Figure 2. NSCs tracking tumor outgrowths and satellites in vivo are likely astrocytic precursors and express CXCR4. -Galactosidase–expressing NSCs tracking
disseminated glioma on histological sections of treated tumor-bearing brains were identified and sections were stained using fluorescent histochemistry for a
variety of neuronal differentiation– and glial differentiation–specific markers. NSCs within tumor outgrowths and satellites were positive for the astrocytic precursor
markers A2B5 and GFAP (top and center rows, respectively) and negative for the neuronal commitment and differentiation markers E-NCAM and -III tubulin (not
shown). Additionally, tumor-tracking NSCs strongly expressed CXCR4, the cell surface receptor for SDF-1.
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the glutamate transporters EAAT1/EAAT2, which are asso-
ciated with functionally differentiated glial progeny. This may
indicate that tumor-tropic NSCs exhibit an astrocytic precur-
sor phenotype at a more advanced stage of differentiation
than that reported by Rao. Similarly, the expression of GFAP
by these tumor-tracking populations also indicates that these
cells are at a level of fate commitment beyond that of the
previously described bipotent O-2A astroglial- and oligoden-
droglial-restricted precursor [18]. Morphological immaturity
and the absence of EAAT1/EAAT2 indicate that these cells
have, however, not reached astrocytic maturity. In this
context, it is likely that complete differentiation of these
tumor-tropic populations occurs soon after the 1-week time
point analyzed in our experiment, although we have previ-
ously described an abundance of morphologically undiffer-
entiated, transplanted tumor-tropic cells up to 18 days
following intratumoral inoculation of NSCs [3]. Of additional
interest was our observation that expression of the neuronal
markers E-NCAM and b-III tubulin was found in a very small
proportion of transplanted NSC-LacZ. Although the corpus
striatum has been shown to have a predominantly gliogenic
influence on transplanted neural precursors [19], the paucity
of neuronal differentiation we noted may potentially indicate
the presence of factors inhibiting neurogenesis within the
tumor microenvironment.
Based on the known chemotactic involvement of CXCR4
in neuronal and glial precursor migration in the developing
CNS [7,8], we wished to investigate whether this receptor
played a functional role in NSC tropism toward tumor. Our
observation that blocking of CXCR4 inhibits NSC tropism for
glioma in vitro, which was consistently reproducible following
repeated assays, fundamentally supports the involvement of
this receptor in mediating this behavior. It is important to
note, however, that in spite of demonstrating marked reduc-
tions in mean NSC translocation following neutralization of
SDF-1, we were unable to validate these differences statis-
tically, despite repeated experimentation confirming this
inhibitory effect. This may represent a technical issue involv-
ing suboptimal neutralization of soluble chemokine versus
more efficient blocking of cell surface CXCR4, or these
findings may point to a role for additional, as of yet uniden-
tified soluble ligand(s) for CXCR4, possibly further isoform
variants of SDF-1 apart from the a and b subtypes we
neutralized. Nevertheless, as SDF-1/CXCR4–mediated as-
trocytic precursor dissemination may play a key role in the
establishment of a glial scaffold in the developing brain and
the elaboration of SDF-1 by disseminating glioma cells is
implicated as a key factor in their invasive properties, it is
likely that similar mechanisms govern the tropism of NSCs
for migrating glioma cells.
The level of NSC migration we observed toward glioma-
conditioned media in vitro was significantly lower than that
qualitatively predictable based on our previously described
in vivomigration patterns [3]. This is, however, in conjunction
with our finding that tumor-tropic behavior is exhibited prin-
cipally by cells that are progressing toward astrocytic differ-
entiation. As the cells utilized in our in vitro experiments
comprised chiefly of NSCs cultured in conditions designed to
favor maintenance of an undifferentiated state, although
early evidence of eventual neuronal or glial directionality
may still be discernable [12], a lower percentage of commit-
ted and actively differentiating astrocytic precursors would
be expected in these populations. Following in vivo trans-
plantation, however, NSCs respond to predominantly glio-
genic cues inherently present in the corpus striatum,
increasing the numbers of astrocytic progenitors potentially
Figure 3. NSCs demonstrate migratory tropism toward glioma-conditioned
media in vitro. Human and murine fetal NSCs were placed in the upper well of
a two-well chemotaxis chamber system, separated from a lower well
containing various media/culture supernatants by a polycarbonate membrane
with multiple 5-m pores. Following incubation at 37j for 4 hours, media from
the lower chambers were harvested and cells were quantified. Y-axis depicts
percentage of NSCs that migrated into the lower chambers. (A) Results
indicated that human fetal NSCs demonstrated minimal migratory activity
toward normal unconditioned medium, whereas movement toward U87MG
glioma supernatant was significantly higher (P = .005; t-test). Dilution of
glioma media resulted in a significant decrease in NSC chemotaxis (not
shown), indicating that NSC translocation was likely due to a tumor-
elaborated soluble factor. Addition of a neutralizing antibody against one
such potential factor, SDF-1, reduced chemotaxis noticeably compared to
NSCs treated with nonspecific isotype IgG, albeit not to a statistically
significant extent (P = .09; t-test). (B) Murine fetal NSCs demonstrated
enhanced migratory activity toward GL26-conditioned medium compared to
control media (P = .0001; t-test). Addition of an anti-CXCR4 neutralization
antibody significantly decreased NSC translocation toward glioma-condi-
tioned media compared to NSCs treated with nonspecific isotype IgG
(P = .003; t-test).
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responsive to chemotactic signals emanating from dissem-
inating tumor cells. This is further supported by our obser-
vation that NSC populations maintained in culture contain
numerous cells positive for the uncommitted precursor
marker Sox-2 (M. Ehtesham, unpublished results), whereas
expression of this factor was very weak in transplanted NSC-
LacZ 1 week following in vivo inoculation (Table 1). These
findings may support a rationale for intratumoral transplan-
tation of partially differentiated CXCR4+ astrocytic progeni-
tors rather than generalized pools of NSCs. In particular,
engineering A2B5/GFAP+ astrocytic precursors to overex-
press CXCR4 may prove an attractive strategy to promote
glioma tropism and improve the therapeutic potential of
these cells. However, given that cerebral white matter—the
most relevant site for inoculation of tumor therapeutic
NSCs—is known to already provide an environment favoring
differentiation of NSCs into astrocytes, it is unclear whether
introduction of partially differentiated cells would provide any
tangible benefit as opposed to the use of uncommitted NSCs.
Also of interest was our finding that primary murine fetal
NSCs exhibited significantly more migration, even toward
unconditioned media, as opposed to human fetal NSCs. This
may be explained by the differing origins of these cultures.
Murine NSCs were derived from primary fetal tissue, where-
as human fetal NSCs were cultured from a several-year-old,
cryopreserved, commercially available stock. It is possible
that freshly generated primary murine cells displayed a
more active migratory capacity as opposed to the human
NSCs, whose biological activity may have been hampered
secondary to prolonged cryogenic storage. Additionally,
human NSCs were subjected to repeated passaging prior
to their storage, which may also have altered their pheno-
typic characteristics, making them less responsive to glioma-
elaborated chemotactic cues.
Given the abysmal prognoses associated with high-grade
gliomas, there is an urgent need to develop novel therapies
with translational potential. Currently, the use of NSCs as
therapeutic delivery vehicles has offered encouraging results
in preclinical models. The use of this technology in patients
is still, however, hampered by significant limitations, key
among which is the isolation of clinically viable and legally
utilizable sources of tumor-tropic neural progenitors. Prog-
ress is, however, being made on this front as exemplified by
recent reports by our group and others regarding alternative
tissue sources from which multipotent neural precursors can
be derived [20,21]. Additionally, preliminary evidence indi-
cates that these cells may also be tactic for migrating glioma
cells (P. Kabos, unpublished results). The identification of
CXCR4 as a key element governing the process of neural
precursor migration toward glioma cells may allow for more
efficient isolation of potentially tumor-tropic cells from these
alternative tissues, thereby hastening the therapeutic testing
of glioma-tracking neural precursors in a clinical setting.
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